Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/ARBs have lower adverse drug reaction risk than ACE inhibitors
Safety · ACEARB-SAFE-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Across several adult studies, people taking ARBs reported dry cough far less often than those taking ACE inhibitors, and the one large trial that measured both problems also found fewer cases of the dangerous throat-swelling reaction called angioedema. The clearest single piece of evidence is a head-to-head trial of telmisartan versus ramipril [11], backed by a prescription-monitoring cohort [7] and two further trials [4][13], with the post-heart-attack trial [1] pointing the same way. Angioedema is much rarer, so it is harder to measure, and only two studies compared it directly between the two drug classes [11][24]. One pooled analysis in children found no significant cough difference [9], which is why the evidence is read as strong in adults rather than universal. The panel treated the direction as consistent and well supported while noting the gaps around children, rare events, and the specific drugs tested.
Cough is lower with ARBs across independent designs and populations: the ONTARGET RCT reported 1.1% versus 4.2% (P<0.001) [11], a prescription-event-monitoring cohort of over 9,000 patients per drug found cough rates significantly higher for three ACE inhibitors than losartan (rate ratios 1.5, 4.8, 5.7, all P<0.03) [7], a trial in rechallenge-confirmed ACEi-cough patients found losartan significantly lower than lisinopril [4], and CORD reported dry cough more frequent with ramipril (33 vs 4, p<0.001) [13], with VALIANT concordant in direction [1]. For angioedema, ONTARGET reported 0.1% versus 0.3% (P=0.01) [11] and a large ONTARGET-emulation cohort reported HR 0.56 (95% CI 0.46-0.67) for ARB versus ACEi [24]. The only explicit cough null is a pediatric pooled analysis of eight trials, 3.2% versus 1.8%, P=0.34 [9]. Several corpus papers describing a lower ARB risk of cough and angioedema are reviews [17][19][21][26] and were excluded from the scoring base by the study-type filter. The contested point: The evidence divides on scope rather than direction: the strength term 'significantly' holds in every adult head-to-head reporting a p-value but fails in the pediatric pooled analysis [9], and the angioedema half rests on only two direct datasets [11][24] with tiny absolute differences (0.1% vs 0.3%) [11]. The emulation cohort [24] further shows the angioedema benefit varies by ethnicity on the additive scale.
All 29 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The pediatric pooled analysis [9] found cough 3.2% (ACEi) vs 1.8% (ARB) with P=0.34 — the 'significantly lower' term fails in children, so the claim is population-contingent rather than universal.
The angioedema half of the claim rests on only two direct head-to-head datasets [11][24]; [1] VALIANT does not report angioedema, and [2][3] give ACEi-only rates. Angioedema is rare and absolute differences are tiny (0.1% vs 0.3%), so statistical significance does not equal a large effect.
Where it remains uncertain. A pediatric pooled analysis found no significant cough difference (3.2% vs 1.8%, P=0.34) [9], and the angioedema effect, though significant, is absolute-small and rests on only two direct comparisons [11][24].
Aleatory
Angioedema is rare and absolute differences are tiny (0.1% vs 0.3% in [11]), so small event counts carry wide uncertainty even where p-values are significant.
The load-bearing papers from a corpus of 29, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Large RCT concordant in direction for cough (no significance test reported)
“With monotherapy, hypotension and renal dysfunction were more common in the valsartan group, and cough, rash, and taste disturbance were more common in the captopril group.”
Panel auditInternal validity: high · scope of inference: Post-myocardial-infarction patients with LV dysfunction or heart failure, valsartan vs captopril.Key limitations: no cough rates or p value · angioedema not reported · post-MI population only
RCT: cough significantly lower with ARB (selected prior-cough population)
“The incidence of cough related to the type 1 Ang II receptor antagonist losartan is significantly lower than that observed with lisinopril”
Panel auditInternal validity: medium · scope of inference: Hypertensive patients with confirmed prior ACEi-related cough, cough recurrence on losartan vs lisinopril.Key limitations: enriched prior-cough population · cough only · small sample
Independent PEM cohort: cough significantly higher for ACEIs
“rates of cough were significantly higher for the three ACEIs when compared with losartan (rate ratios 1.5, 4.8 and 5.7, all P<0.03)”
Panel auditInternal validity: medium · scope of inference: General-practice patients, cough reports for losartan vs three ACEIs.Key limitations: observational · carry-over confounding · cough only
No ARB arm exists; the comparison is race within ACEi users, not ARB vs ACEi.
Panel auditInternal validity: medium · scope of inference: Risk factors (race, early use) for ACEi angioedema in a Medicaid population.Key limitations: no ARB comparator · retrospective · angioedema only
4 of 29 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Convergent, independent primary RCT and cohort evidence supports both outcomes in adults, with only a pediatric exception, warranting the Established band at its conservative floor.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Angioedema magnitude and subgroup consistency. Angioedema rests on two datasets [11][24] with tiny absolute differences and additive-scale ethnic heterogeneity in [24]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A large multi-ethnic cohort or trial-emulation reporting absolute angioedema risk differences by ethnicity for ARB versus ACEi.
Open question: Does the lower ARB cough rate hold in treatment-naive adults rather than only in patients selected for prior ACEi cough? Why it is still open: The strongest significant cough RCT [4] used a rechallenge-confirmed population, an enriched design the Sceptic flagged.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19